ACM
CORT icon

ADAR1 Capital Management’s Corcept Therapeutics CORT Stock Holding History

ADAR1 Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,000
Closed -$322K – 294
2026
Q1 		$322K Buy
+8,000
New +$299K 0.02% 235

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's CORT Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 8,000 shares — an estimated $322K sold.

ADAR1 Capital Management first reported a position in CORT in Q1 2026 and held it in 1 quarter. The position peaked at $322K in Q1 2026. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 8,000 Corcept Therapeutics shares in Q2 2026, an estimated $322K.
  • ADAR1 Capital Management first reported a position in Corcept Therapeutics in Q1 2026 and held it in 1 quarter.
  • ADAR1 Capital Management's Corcept Therapeutics position peaked at $322K in Q1 2026.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.